Management strategies for hepatocellular carcinoma: old certainties and new realities

摘要: Hepatocellular carcinoma (HCC) is a highly prevalent disease ranking among the ten most common cancers worldwide with increasing trend of incidence in developed countries. The great healthcare costs and economic burden HCC dictate proper preventive interventions as well surveillance screening programs to decrease allow early diagnosis. treatment outcomes are affected by several variables, including liver function, patient's performance status, tumor stage. In line Barcelona Clinic Liver Cancer (BCLC) staging curative treatments, such surgery or radio-frequency ablation, indicated early-stage (BCLC-A), noncurative treatments intermediate advanced stages (BCLC-B, C). Transarterial chemoembolization (TACE) represents choice for intermediate-stage Child-Pugh A cirrhosis, long-term survival after transplantation inferior that HCCs. advanced-stage when complete necrosis not achieved recurrence TACE develops, individualized systemic combined radiation therapy indicated. knowledge genomic landscape development molecular-targeted therapies heading toward expanding armamentarium management.